The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis:A Prospective Study by Crichton, Megan L. et al.
                                                                    
University of Dundee
The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in
Bronchiectasis
Crichton, Megan L; Shoemark, Amelia; Chalmers, James D
Published in:







Link to publication in Discovery Research Portal
Citation for published version (APA):
Crichton, M. L., Shoemark, A., & Chalmers, J. D. (2021). The Impact of the COVID-19 Pandemic on
Exacerbations and Symptoms in Bronchiectasis: A Prospective Study. American Journal of Respiratory and
Critical Care Medicine. https://doi.org/10.1164/rccm.202105-1137LE
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. Jul. 2021
The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A 
Prospective Study
Megan L Crichton, BSc, Amelia Shoemark, PhD, James D Chalmers, MD, PhD
Division of Molecular and Clinical Medicine, University of Dundee, Dundee, United Kingdom
Corresponding author: James D. Chalmers, MD, PhD, Division of Molecular and Clinical Medicine, 
University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY. 
jchalmers@dundee.ac.uk
Running head: COVID-19 social distancing and bronchiectasis exacerbations
Subject category: 10.16: Non-cystic fibrosis bronchiectasis
Author contribution: Conception and design: MLC, AS, JDC. Analysis and interpretation: 
MLC, AS, JDC. Drafting the manuscript for important intellectual content: MLC, AS, JDC. 
Word count of the manuscript: 1116
Supported by: This work was supported by the Innovative Medicines Initiative (IMI) and EFPIA 
companies under the European Commission funded project, and iABC (grant 115721), the European 
Respiratory Society through the EMBARC2 consortium and the United States BRR / COPD 
Foundation. EMBARC2 is supported by project partners Astrazeneca, Chiesi, Grifols, Janssen, Insmed, 
Novartis and Zambon. JDC is supported by the GSK/British Lung Foundation Chair of Respiratory 
Research
This article is open access and distributed under the terms of the Creative Commons Attribution 
Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
For commercial usage and reprints please contact Diane Gern (dgern@thoracic.org).
Page 1 of 10
 AJRCCM Articles in Press. Published July 15, 2021 as 10.1164/rccm.202105-1137LE 
 Copyright © 2021 by the American Thoracic Society 
The underlying mechanisms leading to bronchiectasis symptoms and exacerbations are poorly 
understood. Recent data suggests that daily symptoms such as cough and sputum are linked to 
airway bacterial load and corresponding neutrophilic inflammation.1–3 In contrast, recent data 
suggests bronchiectasis exacerbations arise due to changes in the interactions between pathogens in 
the airway microbiome that may be disrupted by viral infections.4 Respiratory viruses can be 
identified during exacerbations in up to 50% of bronchiectasis patients.5 The COVID-19 pandemic 
resulted in the introduction of social distancing and mitigation measures that have reduced person 
to person interactions worldwide.6 This has reduced the circulation of respiratory viruses such as 
influenza and rhinovirus which are commonly identified in exacerbations of bronchiectasis.5 The 
COVID-19 pandemic therefore represents a “natural experiment” to test the hypothesis that many 
bronchiectasis exacerbations are related to external exposures while daily chronic symptoms such as 
cough and sputum are more “intrinsic”. In this study we therefore hypothesised that social 
distancing during 2020 would be associated with reduced reported exacerbations but no change in 
chronic symptoms typically experienced during stable state.
We performed a prospective observational study embedded within the EMBARC registry of patients 
with CT confirmed bronchiectasis, enrolled at Ninewells Hospital, Dundee, UK. Patients were 
enrolled between June 2019 and February 2020 as part of a study to validate a novel patient 
reported outcome measure (the Bronchiectasis Impact Measure - BIM) which has recently been 
reported (Ethical approval: 19/NW/03/64).7 
An amendment to the protocol was made at the onset of the COVID-19 pandemic to administer 
additional BIM and quality of life bronchiectasis questionnaires during the UK first lockdown period 
as a measure of symptoms during a period of social distancing. COVID-19 data collection for 
symptoms took place May-July 2020. Patients symptoms during lockdown were compared to their 
most recent stable pre-lockdown symptom questionnaire. All questionnaires were performed while 
patients were clinically stable and free from exacerbation. Exacerbation frequency during 23rd March 
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to 22nd March 2018/19, 2019/20 and 2020/21 were recorded through the EMBARC registry.8 Dates 
were selected so that the 2020/21 period started with the beginning of the first national lockdown in 
the UK.  Exacerbations were reported by patients and verified by prescription for antibiotics. 
Symptom and exacerbation data were not normally distributed and so are compared using Wilcoxon 
paired signed rank test. Negative binomial regression was used to model exacerbation rates over 
time. 
We included 173 patients in the original study. 19 patients were lost to follow-up and 7 patients had 
died, resulting in 147 patients included in the present analysis. The median age (interquartile range) 
was 70 years (64-75), 84 (57.1%) patients were female. The mean baseline FEV1 was 84.0% predicted 
(standard deviation 28.4). The median bronchiectasis severity index score was 6 (4-9). 64 (43.5%) 
had Haemophilus influenzae chronic infection and 25 (17.0%) had Pseudomonas aeruginosa chronic 
infection. 82.1% of the patients reported to be “shielding” during the pandemic. ‘Shielding’ was used 
to describe recommended additional protective measures encouraged in the UK for people who 
were at high-risk and extremely vulnerable, this included leaving their homes as little as possible and 
minimising all person to person contact. Only 2 patients in the cohort had PCR confirmed SARS-CoV-
2 infection.
There was a statistically significant reduction in the frequency of reported exacerbations during the 
lockdown period. The number of exacerbations per patient per year was 2.08 in 2018/19, 2.01 in 
2019/20 and 1.12 in 2020/21. Figure 1 shows that the number of patients experiencing no 
exacerbations over a 12 month period increased from 22.4% in 2018/19, 25.6% in 2019/20 to 52.3% 
in 2020/21. Paired data between years was compared using the Wilcoxon matched pair sign rank 
test, demonstrating a significant reduction in exacerbations between 2020/21 and both 2018/19 and 
2019/20 (p<0.0001 for both comparisons). The proportion of patients experiencing a hospitalization 
due to severe exacerbation was 8.8%, which was lower than 14.3% and 16.3% in the two previous 
years respectively. We analysed which clinical parameters were associated with continuing to have 
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exacerbations during 2020/21 in a negative binomial model and significant associations were found 
for prior exacerbation frequency (rate ratio 1.20 (1.07-1.35,p=0.002) and chronic P. aeruginosa 
infection (RR 1.78 95% 1.01-3.14,p=0.047). 
After adjusting for prior exacerbation history, patients with more severe symptoms were more likely 
to experience exacerbations during 2020/21 including sputum production RR 1.14 95%CI 1.05-
1.24,p=0.002, dyspnoea RR 1.11 95%CI 1.02-1.21,p=0.018, tiredness RR 1.14 95%CI 1.04-
1.24,p=0.004, activity RR 1.13 95%CI 1.03-1.23,p=0.007, overall health RR 1.11 95%CI 1.02-
1.21,p=0.022 and control RR 1.12 95%CI 1.03-1.22,p=0.006. The only domain not significantly 
associated with exacerbations was cough RR 1.08 95%CI 0.99-1.18,p=0.07.
Comparing patients symptoms using the BIM pre- and during lockdown, there were no significant 
differences in the impact of cough, sputum, dyspnoea, tiredness, activity, overall health, control and 
exacerbations on quality of life (table 1). This was also noted in the QOL-B where no significant 
change was seen in the respiratory symptoms score which was completed alongside the BIM at each 
timepoint. It should be noted that the BIM questionnaire asks about the impact of exacerbations on 
quality of life, not the frequency of exacerbations.
In summary, bronchiectasis exacerbation frequency was markedly reduced between March 2020 
and March 2021 compared to the same time periods in the previous 2 years. Respiratory symptoms 
were unchanged during the pandemic from the pre-pandemic period. Our data support a key role 
for external environmental factors in the pathogenesis of bronchiectasis exacerbations. While a 
reduction in circulating viruses is the most likely reason for reduced exacerbation frequency5, there 
are other potential contributors to our findings including reductions in traffic related air pollution 
which were documented during the lockdown periods.9 Although reduced access to healthcare, or 
avoidance of healthcare contacts by patients are a potential alternative explanation for our findings, 
this seems less likely because access to primary and secondary care were largely maintained in the 
region via virtual appointments during the study period. We might also expect that if patients had 
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exacerbations which were not treated, we would see a deterioration in symptoms or an increase in 
severe exacerbations requiring hospitalisation, neither of which were observed. Results of our study 
are consistent with observations in other diseases such as COPD where exacerbation frequency has 
reduced during lockdown periods.10 Our study has limitations including single centre design, the 
relatively small sample size and the lack of data on viruses at exacerbation to confirm the 
mechanism of exacerbation reduction. Our study also has unique strengths in that we could perform 
symptom and exacerbations assessments in a standardised fashion within a cohort established 
before the pandemic. 
In summary, social distancing measures during the first 12 months of the COVID-19 pandemic were 
associated with a marked reduction in bronchiectasis exacerbations but no change in individual 
chronic respiratory symptoms. 
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Questionnaire Symptom Pre-lockdown lockdown p-value
Cough 4.0 (1.1-7.0) 3.1 (1.0-7.0) 0.19
Sputum 3.7 (1.0-7.0) 3.8 (1.0-7.0) 0.89
Dyspnoea 5.0 (1.5-75) 4.9 (2.0-7.5) 0.19
Tiredness 6.0 (2.0-8.0) 5.0 (2.6-8.0) 0.79
Activity 4.0 (1.0-8.0) 4.0 (1.0-7.0) 0.67
Overall health 3.0 (1.0-7.0) 4.0 (1.0-7.0) 0.31





3.0 (1.0-8.0) 3.9 (1.0-7.0) 0.82





70.4 (55.6-81.5) 70.4 (51.9-81.5) 0.56
Table 1. Change in disease impact during the pre- and pandemic periods. Patients most recent stable 
BIM questionnaire and their “lockdown” questionnaire performed during June/July 2020 are 
compared. Symptom data are presented as median (interquartile range) p-values calculated by 
Wilcoxon paired sign rank test. 
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Figure 1. Absolute number of patients experiencing 0, 1, 2 and 3 or more exacerbations per year 
during the 3 years of observation. (n=147 total patients for each year). 
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